Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
United Therapeutics Corporation
UTHR
NASDAQ·Healthcare·Biotechnology·Mkt cap $23.2B
$555.91
▲ +1.60%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$272.12 - $609.35
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 85.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized rare disease focus
- Comprehensive PAH treatment portfolio
- Advanced R&D pipeline
- Targeted therapeutic innovations
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Expanding PAH treatment market
Value
Attractively priced below Biotech & Therapeutics peer average
Momentum
Stable
-3.1% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying UTHR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 28, 2026
MAY 6, 2026
Reported EPS of $5.82 vs $7.00 consensus (-16.9% surprise). Revenue of $781.5M vs $797.4M expected (-2.0%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-16.9%
Next: Apr 28, 2026
Revenue trend · last 8Q
—
—
+20%
+17%
+12%
+7%
+7%
-2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$714.9M
$748.9M
$735.9M
$794.4M
$798.6M
$799.5M
$790.2M
$781.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
35.2%
Wall Street consensus
9 analysts · 78% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
78%
Hold
22%
Sell
0%
Median Price Target
$609.50
▲ +9.6% vs $555.91
Latest: Morgan Stanley · $516.00 · May 7, 2026
3 analysts covering
vs Industry
How UTHR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related